Baldwin Investment Management’s Immunome IMNM Stock Holding History

Baldwin Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$570K	Sell	25,394 -21,773	-46%	-$485K	0.07%	147
2025 Q4	$1.01M	Buy	47,167 +21,773	+86%	+$382K	0.11%	110
2025 Q3	$297K	Hold	25,394	–	–	0.03%	182
2025 Q2	$236K	Hold	25,394	–	–	0.03%	196
2025 Q1	$171K	Hold	25,394	–	–	0.02%	199
2024 Q4	$270K	Hold	25,394	–	–	0.04%	180
2024 Q3	$371K	Hold	25,394	–	–	0.05%	172
2024 Q2	$307K	Hold	25,394	–	–	0.04%	177
2024 Q1	$627K	Hold	25,394	–	–	0.09%	136
2023 Q4	$272K	Hold	25,394	–	–	0.04%	180
2023 Q3	$212K	Hold	25,394	–	–	0.04%	185
2023 Q2	$201K	Hold	25,394	–	–	0.03%	195
2023 Q1	$127K	Hold	25,394	–	–	0.02%	198
2022 Q4	$56.1K	Hold	25,394	–	–	0.01%	195
2022 Q3	$113	Hold	25,394	–	–	0.02%	197
2022 Q2	$82	Hold	25,394	–	–	0.02%	215
2022 Q1	$144	Buy	+25,394	New	+$190K	0.02%	241
2021 Q4	–	Sell	-9,196	Closed	-$224K	–	259
2021 Q3	$224K	Buy	+9,196	New	+$160K	0.04%	231
2021 Q2	–	Sell	-25,394	Closed	-$860K	–	256
2021 Q1	$860K	Buy	+25,394	New	+$631K	0.16%	111

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Baldwin Investment Management's IMNM Position: Q1 2026 in Review

Baldwin Investment Management reduced its Immunome (IMNM) stake by 46% in Q1 2026, selling an estimated $485K and leaving 25,394 shares worth $570K. The position accounts for 0.07% of the portfolio, ranked #147.

Baldwin Investment Management first reported a position in IMNM in Q1 2021 and has held it in 19 quarters since. The position peaked at $1.01M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Baldwin Investment Management held 25,394 shares of Immunome worth $570K as of Q1 2026.
Baldwin Investment Management sold 21,773 Immunome shares in Q1 2026, an estimated $485K.
Immunome made up 0.07% of Baldwin Investment Management's portfolio in Q1 2026, its #147 holding.
Baldwin Investment Management first reported a position in Immunome in Q1 2021 and has held it in 19 quarters since.
Baldwin Investment Management's Immunome position peaked at $1.01M in Q4 2025.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Baldwin Investment Management's 13F filing for Q1 2026, filed 12 May 2026.